Vegt P D, Witjes J A, Witjes W P, Doesburg W H, Debruyne F M, van der Meijden A P
Department of Urology, Rijnland Hospital, Leiderdorp, Bosch Medical Centre, Hertogenbosch, The Netherlands.
J Urol. 1995 Mar;153(3 Pt 2):929-33.
Results of a randomized prospective study are reported in which mitomycin C, Tice bacillus Calmette-Guerin (BCG) and RIVM-BCG were compared in 437 patients with primary or recurrent pTa and pT1 bladder tumors, including carcinoma in situ. The followup (or time in study) varied from 2 to 81 months (mean 36 months). After complete transurethral resection of all visible tumors the patients were treated with 30 mg. mitomycin C once a week for 4 consecutive weeks and thereafter every month for a total of 6 months, and 5 x 10(8) colony-forming units Tice BCG or RIVM-BCG once a week for 6 consecutive weeks. For papillary tumors mitomycin C and RIVM-BCG treatments were equally effective (p = 0.53), and mitomycin C was more effective than Tice BCG therapy (p = 0.01).
本文报告了一项随机前瞻性研究的结果，该研究比较了丝裂霉素C、蒂策卡介苗（BCG）和荷兰国家公共卫生与环境研究所卡介苗（RIVM-BCG）在437例原发性或复发性pTa和pT1膀胱肿瘤患者（包括原位癌）中的疗效。随访时间（或研究时间）为2至81个月（平均36个月）。在经尿道完全切除所有可见肿瘤后，患者接受30毫克丝裂霉素C治疗，每周一次，连续4周，此后每月一次，共6个月；以及5×10⁸集落形成单位的蒂策卡介苗或荷兰国家公共卫生与环境研究所卡介苗，每周一次，连续6周。对于乳头状肿瘤，丝裂霉素C和荷兰国家公共卫生与环境研究所卡介苗治疗效果相当（p = 0.53），且丝裂霉素C比蒂策卡介苗治疗更有效（p = 0.01）。
